Industry Strength Score
66/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
BITWISE MARA INCOME STRAT (IMRA) Stock Price & Overview
NYSEARCA:IMRA • US0917487078
Current stock price
15.1771 USD
-0.19 (-1.24%)
At close:
15.22 USD
+0.04 (+0.28%)
Pre-Market:
The current stock price of IMRA is 15.1771 USD. Today IMRA is down by -1.24%. In the past month the price increased by 18.75%. In the past year, price decreased by -73.32%.
IMRA Key Statistics
52-Week Range11.99 - 60.7276
Current IMRA stock price positioned within its 52-week range.
1-Month Range12.25 - 15.81
Current IMRA stock price positioned within its 1-month range.
- Market Cap
- 398.155M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- N/A
- Dividend Yield
- N/A
IMRA Stock Performance
Today
-1.24%
1 Week
-3.15%
1 Month
+18.75%
3 Months
-2.04%
Longer-term
6 Months -52.37%
1 Year -73.32%
2 Years N/A
3 Years N/A
5 Years N/A
10 Years N/A
IMRA Stock Chart
IMRA Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to IMRA. When comparing the yearly performance of all stocks, IMRA is a bad performer in the overall market: 92.18% of all stocks are doing better.
Chartmill TA Rating
Chartmill Setup Rating
IMRA Industry Overview
IMRA operates in the Pharmaceuticals sub-industry within the Health Care sector. This group contains 135 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Growth Score
16/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
35%
Outperformed 35% of sub-industries
3 Month Rank
49%
Outperformed 49% of sub-industries
6 Month Rank
37%
Outperformed 37% of sub-industries
Industry Fundamentals & Breadth
- Members
- 135
- New Highs
- 3.7%
- New Lows
- 4.4%
- Average ROE
- 50.6%
- Average Profit Margin
- 27.8%
- Average Operating Margin
- 37.5%
- Average P/E
- 25.0
- Average Fwd P/E
- 19.7
- Average Debt/Equity
- 1.2
IMRA Competitors/Peers
The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 24.34 | 804.24B | ||
| JNJ | JOHNSON & JOHNSON | 17.92 | 547.597B | ||
| MRK | MERCK & CO. INC. | 21.79 | 274.033B | ||
| PFE | PFIZER INC | 8.79 | 149.376B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.1 | 117.584B | ||
| ZTS | ZOETIS INC | 16.09 | 47.868B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.58 | 28.553B | ||
| VTRS | VIATRIS INC | 6 | 17.431B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 20.72 | 10.887B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 9.409B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 6.108B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.796B | ||
| CORT | CORCEPT THERAPEUTICS INC | 85.86 | 4.956B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the NYSE Arca Exchange | Find more ETFs on the USA exchanges | Find stocks with similar TA and Setup ratings on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges
BITWISE MARA INCOME STRAT / IMRA FAQ
What does IMRA do?
Imara, Inc. is a clinical-stage biopharmaceutical company. The company is headquartered in Brookline, Massachusetts and currently employs 6 full-time employees. The company went IPO on 2020-03-12. The firm is focused on developing and commercializing therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin and other serious diseases. Its lead product candidate, tovinontrine (IMR-687), is an oral, highly selective, potent small molecule inhibitor of phosphodiesterase-9 (PDE9). PDE9 selectively degrades cyclic guanosine monophosphate (cGMP), an active signaling molecule. IMR-687 is in Phase IIb clinical development for the treatment of sickle cell disease (SCD) and beta- thalassemia. The company is also focused on initiating a Phase II clinical trial of IMR-687 in heart failure with preserved ejection fraction (HFpEF). The firm is also focused on development of IMR-261, an oral, clinic-ready activator of nuclear factor erythroid 2-related factor 2 (Nrf2).
What is the current price of IMRA stock?
The current stock price of IMRA is 15.1771 USD. The price decreased by -1.24% in the last trading session.
What is the ChartMill technical and fundamental rating of IMRA stock?
IMRA has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 0 out of 10.